Molecular Profiling in Asia: The Current Status and Approach.
- 1Department of Medical Oncology & Precision Oncology, Sir H.N. Reliance Foundation Hospital and Medical Research Center, Mumbai, Maharashtra, India.
- 2Department of Clinical Oncology, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, China.
- 3Division of Hematology, Mayo Clinic, Rochester, MN, USA.
Abstract
Precision oncology has transformed cancer care globally through biomarker-driven and genomically guided treatment strategies. In Asia, where nearly 60% of the world's population resides, the implementation of molecular profiling presents both significant opportunities and unique challenges. Despite increasing adoption, precision diagnostics remain largely concentrated in urban and academic centers, with disparities in access, infrastructure, and expertise across the region. Advances in next-generation sequencing (NGS), including targeted gene panels, comprehensive genomic profiling, whole exome sequencing, and whole-genome sequencing, have enabled the identification of actionable alterations across multiple tumor types. Liquid biopsy approaches, including circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs), are further transforming cancer care by enabling real-time disease monitoring and detection of resistance mechanisms. Integration of multiomics platforms is increasingly enhancing clinical decision-making. Molecular tumor boards play a critical role in interpreting complex genomic data and facilitating genomically guided treatment decisions, including targeted therapy selection, off-label treatment recommendations, and clinical trial enrollment. However, several barriers continue to limit widespread implementation of genetic testing in Asia, including high costs, limited reimbursement, inadequate infrastructure, lack of trained personnel, and insufficient genomic databases representing Asian populations. This review provides a comprehensive overview of current molecular diagnostic approaches, clinical applications, and evolving precision oncology practices in Asia. We also highlight key challenges and propose practical solutions, including physician and patient education, expansion of trial-matching platforms, and development of region-specific genomic datasets. Strengthening these areas will be essential for advancing equitable, accessible, and effective precision cancer care across Asia.
Related
- Current Status and Future Perspectives of Robotic Surgery for Esophagogastric Cancer in Asia
- Molecular Detection Technologies for Helicobacter pylori Antibiotic Resistance: Current Status and Clinical Implications.
- From epidemiology to molecular pathology: current research status and future prospects on the role of toxic metal exposure in the development and progression of bladder cancer
- Women's health and female fertility: current evidence and knowledge gaps in the Asia–Pacific region
- Building cardio-oncology nursing capacity in Asia: Current practice and future directions.
BibTeX
@article{limaye2026molecular,
title = {{Molecular Profiling in Asia: The Current Status and Approach.}},
author = {Sewanti Limaye and Herbert Loong and Mahin Bhatt and Ka Hei Chan},
journal = {Journal of immunotherapy and precision oncology},
year = {2026},
month = nov,
doi = {10.36401/jipo-26-14},
url = {https://europepmc.org/article/MED/42999819},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Molecular Profiling in Asia: The Current Status and Approach.
AU - Sewanti Limaye
AU - Herbert Loong
AU - Mahin Bhatt
AU - Ka Hei Chan
PY - 2026
DA - 2026/11/05
JO - Journal of immunotherapy and precision oncology
DO - 10.36401/jipo-26-14
UR - https://europepmc.org/article/MED/42999819
AB - Precision oncology has transformed cancer care globally through biomarker-driven and genomically guided treatment strategies. In Asia, where nearly 60% of the world's population resides, the implementation of molecular profiling presents both significant opportunities and unique challenges. Despite increasing adoption, precision diagnostics remain largely concentrated in urban and academic centers, with disparities in access, infrastructure, and expertise across the region. Advances in next-generation sequencing (NGS), including targeted gene panels, comprehensive genomic profiling, whole exome sequencing, and whole-genome sequencing, have enabled the identification of actionable alterations across multiple tumor types. Liquid biopsy approaches, including circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs), are further transforming cancer care by enabling real-time disease monitoring and detection of resistance mechanisms. Integration of multiomics platforms is increasingly enhancing clinical decision-making. Molecular tumor boards play a critical role in interpreting complex genomic data and facilitating genomically guided treatment decisions, including targeted therapy selection, off-label treatment recommendations, and clinical trial enrollment. However, several barriers continue to limit widespread implementation of genetic testing in Asia, including high costs, limited reimbursement, inadequate infrastructure, lack of trained personnel, and insufficient genomic databases representing Asian populations. This review provides a comprehensive overview of current molecular diagnostic approaches, clinical applications, and evolving precision oncology practices in Asia. We also highlight key challenges and propose practical solutions, including physician and patient education, expansion of trial-matching platforms, and development of region-specific genomic datasets. Strengthening these areas will be essential for advancing equitable, accessible, and effective precision cancer care across Asia.
SN - 2666-2345
SN - 2590-017X
ER -